Podcasts about Clinical

AI is transforming medicine at a speed never seen before. In this episode, you'll discover how digital twins and artificial intelligence will revolutionize drug discovery, eliminate human trials, and personalize your biology for longevity and high performance. Host Dave Asprey breaks down how AI can now simulate virtual cells and tissues, running clinical experiments in minutes instead of years to create truly individualized medicine. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Dr. Derya Unutmaz is a world-renowned immunologist, systems biologist, and professor at The Jackson Laboratory. With more than 150 scientific papers, he's a leading expert in immune system research and one of the first scientists to pioneer the concept of digital twins for biology. His groundbreaking work uses AI to model how immunity, metabolism, and aging interact—creating new possibilities for personalized medicine, disease prevention, and lifespan extension. Host Dave Asprey and Dr. Unutmaz reveal how AGI will soon outperform doctors, accelerate functional medicine, and optimize human biology far beyond today's standards. You'll learn how the immune system drives inflammation and aging, how to re-engineer it for resilience, and why compounds like GLP-1 and metformin may add years to your life. You'll Learn: • How digital twins will end human drug testing • Why AGI could replace doctors and computer jobs within five years • How AI models immune function, metabolism, and aging • The role of mitochondria and inflammation in longevity • How GLP-1 drugs and metformin extend lifespan • What continuous biological monitoring means for health tracking • How AI is transforming functional medicine and personalized care • Why NAD and energy metabolism are key to human performance They explore how artificial intelligence, biohacking, and systems biology intersect to create a smarter approach to health and longevity. You'll also learn how understanding immune balance, metabolism, and mitochondrial function helps build resilience and extend your lifespan. This is essential listening for anyone serious about biohacking, hacking human performance, and extending longevity through personalized medicine, functional biology, and cutting-edge AI innovation. This is essential listening for anyone serious about biohacking, hacking human performance, improving mobility, and extending longevity. You'll also learn how neuroplasticity, metabolism, and brain optimization all connect to the way you move. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: AI medicine, Digital twins, Functional medicine, Biohacking, Longevity, Immune system, Inflammation, Personalized medicine, GLP-1 therapy, Metformin, NAD boosters, Mitochondrial function, Metabolism, AGI, Clinical trials, Human performance, Aging research, Systems biology, Immunology, Smarter Not Harder Thank you to our sponsors! BrainTap | Go to http://braintap.com/dave to get $100 off the BrainTap Power Bundle. MASA Chips | Go to https://www.masachips.com/DAVEASPREY and use code DAVEASPREY for 25% off your first order. Our Place | Head to https://fromourplace.com/ and use the code DAVE for 10% off your order. ARMRA | Go to https://tryarmra.com/ and use the code DAVE to get 15% off your first order Resources: • Keep up with Derya's work: https://x.com/derya_?lang=en • Business of Biohacking Summit | Register to attend October 20-23 in Austin, TX https://businessofbiohacking.com/ • Danger Coffee: https://dangercoffee.com/discount/dave15 • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 00:00 — Trailer 01:25 — Intro 02:26 — AI's Role in Extending Lifespan 02:56 — Regulatory Frameworks and Medical Adoption 05:19 — Problems with the Immune System 08:19 — Chronic Fatigue and Long COVID Research 10:32 — Modern Testing and Multi-Omic Analysis 14:07 — Personal Longevity Strategy and Supplements 15:17 — Understanding Exhausted Cells 23:43 — Personalization in Medicine and AI Analysis 31:35 — Longevity Escape Velocity 36:13 — AI Doctors and Prescriptions 39:55 — Data Quality Concerns in AI Training 43:19 — The Future of Wearable Technology 45:50 — Revolutionizing Education with AI 49:04 — The Future of Higher Education 52:03 — Future of Work and AI Agents See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this new episode, Rabih shares an important case with Debora, Mark, and Noah. We invite you to listen and join in on their journey as they work together to discover the final diagnosis. To join us live on Virtual Morning Report (VMR) or to present a case to us, sign up here.  Download CPSolvers App… Read More »Episode 424 – The Clinical Unknown Series with Debora, Mark, Noah and Rabih

Clinical psychologist Annia Raja discusses her article "Why more physicians are quietly starting therapy." Annia explains how growing numbers of physicians are turning to therapy—not because they are failing, but because they are recognizing they cannot carry the weight of medicine alone. She outlines cultural shifts that are breaking down the "invincible doctor" myth, from generational openness to the impact of the pandemic, and highlights what doctors are really seeking in therapy: depth, safety, and understanding. Annia also emphasizes why quiet participation still matters, how therapy can be an investment in career longevity, and how these changes benefit both physicians and patients. Listeners will take away insights into how therapy is reshaping medical culture and why healing the healers is essential for the future of care. Our presenting sponsor is Microsoft Dragon Copilot. Want to streamline your clinical documentation and take advantage of customizations that put you in control? What about the ability to surface information right at the point of care or automate tasks with just a click? Now, you can. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Offering an extensible AI workspace and a single, integrated platform, Dragon Copilot can help you unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's part of Microsoft Cloud for Healthcare, built on a foundation of trust. Ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

In this throwback episode, Zach and Kevin are joined by Kevin's son and expert on AI in dentistry, Charlie Fryer! Charlie discusses his master's thesis on applying Artificial Intelligence (AI) to the diagnosis of Class II caries (decay) in dentistry. Charlie, a chemical engineer with a background in data science from Georgia Tech, explains the immense, data-intensive challenges of using a deep learning model to create an objective diagnostic tool for Class II decay from bite-wing X-rays. Both hosts express an optimistic view of AI's inevitable and positive integration into dentistry as a tool to flag potential issues for the clinician's review, improving patient care and eliminating missed diagnoses. Join the Very Dental Facebook group using the password "Timmerman," Hornbrook" or "McWethy," "Papa Randy," "Lipscomb" or "Gary!" The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! -- Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code “VERYDENTAL10” you'll get another 10% off your order! Go save yourself some money and support the show all at the same time! -- The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! -- Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! -- CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!      

Today, I'm joined by Dr. Lisa Shah, Chief Medical Officer at Twin Health.   Replacing population averages with personal biomarkers, Twin Health leverages digital twin technology to address root causes of metabolic conditions like obesity and diabetes.   In this episode, we discuss how machine learning is transforming disease management.   We also cover:   Building a GLP-1 off-ramp Balancing AI with human support Achieving a 71% diabetes reversal rate   Subscribe to the podcast → insider.fitt.co/podcast  Subscribe to our newsletter → insider.fitt.co/subscribe  Follow us on LinkedIn → linkedin.com/company/fittinsider    Twin Health's Website: www.twinhealth.com  Dr. Lisa Shah's LinkedIn: https://www.linkedin.com/in/lisa-shah-4a297b19/ Twin Health's Facebook: https://www.facebook.com/twinhealthusa/ Twin Health's Instagram: https://www.instagram.com/twinhealthusa Twin Health's LinkedIn: https://www.linkedin.com/company/twinhealth/   -   The Fitt Insider Podcast is brought to you by EGYM. Visit EGYM.com  to learn more about its smart workout solutions for fitness and health facilities.   Fitt Talent: https://talent.fitt.co/  Consulting: https://consulting.fitt.co/  Investments: https://capital.fitt.co/    Chapters: (00:00) Introduction (02:00) Digital twin technology explained and healthcare applications (04:15) Why digital twin technology is finally possible now (08:30) Turning 3K daily data points into actionable guidance (11:15) Balancing digital twin AI with human care team support (15:00) Clinical outcomes and New England Journal of Medicine study (19:15) Root cause solutions vs symptom management (21:15) Scaling from employer benefits to consumer prevention (24:00) Value-based care approach vs. direct-to-consumer model (27:15) Digital twin complexity across multiple health systems (31:00) Building trust through real-time feedback loops (33:00) Agentic AI applications in healthcare delivery (37:42) Future roadmap (40:15) Conclusion  

In this episode of The Lifestyle Practice Podcast, Dr. Derek Williams and Dr. Steve Van de Graaff open up about the vision, planning, and mindset that allowed them to sell their practices and take extended time away with their families. They share the early influences that shaped their career goals, the numbers and strategies that made financial independence possible, and the emotional challenge of actually pulling the trigger. Whether you dream of early financial freedom or simply want more balance, this conversation offers insights on building a practice that supports your ideal lifestyle—both now and in the future. Connect with us: • Learn more about 1-on-1 coaching • Get access to TLP Academy • Suscribe to The Lifestyle Practice Podcast • Email Derek at derek@thelifestylepractice.com • Email Matt at matt@thelifestylepractice.com • Email Steve at steve@thelifestylepractice.com

Comments or feedback? Send us a text!

In this episode, Sarah E. Ginnetti, Chief Revenue Cycle Officer and VP of Clinical Revenue at UConn Health, discusses her top priorities, the role of AI and analytics in revenue cycle management, and how collaboration across clinical, finance, and strategy teams is shaping the future of healthcare operations.

In his weekly clinical update, Dr. Griffin with Vincent Racaniello chat about the ongoing Ebola outbreak in DRC, increases in screwworm diagnoses, a pertussis death in Mississippi before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, monoclonal antibody therapy against RSV, where to find PEMGARDA, long COVID treatment center, where to go for answers to your long COVID questions, olfactory dysfunction following SARS-CoV-2 infection and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Ebola Disease (WHO: African Region) Mexico sees 32% jump in flesh-eating screwworm cases since August as cases move north (Reuters) Pediatric Pertussis Death Reported (Mississippi State Department of Health) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Measles (CDC: Measles Rubeola) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) Influenza-Associated Pediatric Deaths — United States, 2024–25 Influenza Season (CDC: MMWR) ACIP Recommendations Summary (CDC: Influenza) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season(FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season (JAMA: Open Network) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Evidence to Recommendations Framework (EtR): RSV Vaccination in Adults Aged 50–59 years (CDC: National Center for Immunization and Respiratory Diseases) Efficacy and safety of respiratory syncytial virus vaccines (Cochrane Library) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Olfactory Dysfunction After SARS-CoV-2 Infection in the RECOVER Adult Cohort (JAMA: Open Network) Reaching out to US house representative Letters read on TWiV 1258 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Pharmacists providing care to patients following toxicologic ingestions of medications and other substances are often relied upon for treatment and monitoring recommendations. Many pharmacists do not routinely care for patients following toxicologic ingestions of medications or other substances and are unfamiliar with clinical presentation of various toxidromes and ultimately management strategies. This episode covers anticholinergic, cholinergic, sedative-hypnotic, opioid, sympathomimetic, serotonin syndrome, neuroleptic malignant syndrome, and malignant hypethermia toxidromes and discusses the clinical presentation and causative medications/substances and general treatment approaches, with an emphasis on antidotes for specific toxidromes including physostigmine, naloxone, flumazenil, atropine, and pralidoxime. CE expires two years from when this episode was originally published. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

She had to walk away from her $1M a year business.LIVE recording of Awful Okay Awesome with our guest Dr. Nat Green - our show about how life's trials and tribulations can lead to passion and purpose.Thanks to our sponsors at Black Aswad Coffee. Get your coffee now at blackaswadcoffeeco.com - use code AWESOME15 for a special discount! Love our show? Leave us a 5-star review on our favorite platform.Dr. Nat Green is a Trauma Breakthrough Coach, Bestselling Author, and host of Growing Tall Poppies with a background in Clinical and Health Psychology. She is passionate about transforming lives and revolutionising the trauma landscape.With over 30 years of experience working in trauma and having lived experience with trauma, Dr. Nat is an industry trailblazer. She is the author of ‘Key to Freedom - The 7-Step Model to Triumph Over Trauma' and her latest book ‘Break Your Trauma Cycle: The 7 Archetypes of Transformation', and Creator and Founder of the Accelerated Breakthrough Strategies (ABS) Method®, which accelerates trauma recovery and facilitates transformation into post-traumatic growth.

Our China Healthcare Analyst Jack Lin discusses how China's biotech surge is reshaping healthcare, investment and innovation worldwide.Read more insights from Morgan Stanley.----- Transcript ----- Jack Lin: Welcome to Thoughts on the Market. I'm Jack Lin, from Morgan Stanley's China Healthcare Team. Today, the boom in China biotech – and how it's not just a headline for China-focused investors, but a story that touches all of us. It is Friday, October 3rd at 2pm in Hong Kong. Many people might not realize this but some of the next generation healthcare innovation is being developed far from Silicon Valley and Wall Street. The medicines you rely on, treatment plans that could shape your family's future, even investment opportunity that can grow your savings. They are all increasingly influenced by China's rapidly evolving biotech sector, which is transitioning from traditional generics manufacturing into the global innovation ecosystem. In fact, China's biotech industry is set to become a major player in the global innovation ecosystem. By 2040, we project China's originated assets could represent about a third of U.S. FDA approvals – up dramatically from just 5 percent today. And the question isn't if China's biotech will matter, but how global patients could benefit; and how consumers and investors worldwide might engage with its impact.What's driving this transformation? Three key components are driving the globalization of China originated drug innovations: cost, accessibility, and innovation quality. Lower cost in China's biotech sector enables more efficient development. Clinical trial quality is improving with regulatory pathways becoming more streamlined, promoting accessibility of China innovation for global markets. Finally, innovation in China's biotech sector is gaining momentum with more regionally developed medicines now eyeing market approval from leading overseas agencies like the U.S. FDA and EMA.This is all to say China is on track to become a key force on the global biotech stage. That said, right now we're also at a crossroads moment as geopolitical tensions between U.S. and China pose potential risks to the flow of innovation. Despite these uncertainties, we see a likely outcome of co-opetition, a blend of competition and collaboration, as global pharma grapples with the dual imperatives of innovation and resilience. Of course, this rapid evolution brings both opportunities and challenges. It's prompting stakeholders around the world to rethink their strategies and collaborations in this shifting landscape of global medical innovation. As the China biotech industry evolves, the choices made by investors, policy makers, and healthcare communities, both within China and globally, will determine the therapies of the future. It is truly a dynamic space, and we'll continue to bring you updates. Thanks for listening to our thoughts on the market. If you enjoy the show, please leave us a review, wherever you listen and share Thoughts on the Market with a friend or colleagues today.

John Murray, Ian Dennis & Ali Bruce-Ball talk football, travel & language. They hear from Thomas Tuchel after leaving Bellingham, Foden & Grealish out of his England squad. Plus, John is ‘humbled' by a commentary tattoo, and will anything join the ‘Cruyff Turn' in Division One of the Great Glossary of Football Commentary? Get your suggestions in with WhatsApp voicenotes to 08000 289 369 & emails to TCV@bbc.co.uk02:45 Ali has his car back! 06:05 Thomas Tuchel announces England squad, 13:50 Detailed beard analysis, 18:10 5 Live commentaries this weekend, 19:00 Forest fans turn on Ange Postecoglou, 21:05 Selhurst Park adorned with 5 Live quotes, 22:30 John ‘humbled' by commentary tattoo, 23:35 Can Crystal Palace win the Premier League? 26:20 Ali vs Ian in Clash of the Commentators, 33:00 The Great Glossary of Football Commentary.BBC Sounds / 5 Live Premier League commentaries: Sat 1500 Arsenal v West Ham, Sat 1500 Man Utd v Sunderland on Sports Extra, Sat 1730 Chelsea v Liverpool, Sun 1400 Newcastle v Forest, Sun 1400 Everton v Palace on Sports Extra Sun 1400 Aston Villa v Burnley on BBC Sport website & app, Sun 1400 Wolves v Brighton on BBC Sport website & app, Sun 1630 Brentford v Man City.Glossary so far:DIVISION ONE Bosman, Cruyff Turn, Onion bag, Panenka, Rabona, Where the kookaburra sleeps, Where the owl sleeps, Where the spiders sleep.DIVISION TWO Daisycutter, Howler, One for the cameras, Played us off the park, Purple patch, Root and branch review, Row Z, Taking one for the team, That's great… (football), Thunderous strike.UNSORTED 2-0 is a dangerous score, After you Claude, All-Premier League affair, Aplomb, Bag/box of tricks, Brace, Brandished, Breaking the deadlock, Bundled over the line, Champions elect / champions apparent, Clinical finish, Commentator's curse, Coupon buster, Cultured/Educated left foot, Denied by the woodwork, Draught excluder, Elimination line, Fellow countryman, Foot race, Formerly of this parish, Fox in the box, Free hit, Goalkeepers' Union, Goalmouth scramble, Good touch for a big man, Honeymoon Period, In and around, In the shop window, Keeping ball under their spell, Keystone Cops defending, Languishing, Loitering with intent, Marching orders, Nestle in the bottom corner, Numbered derbies, Nutmeg, Opposite number, Park the bus, PK for penalty-kick, Postage stamp, Put it in the mixer, Put their laces through it, Rasping shot, Red wine not white wine, Relegation six-pointer, Rooted at the bottom, Route One, Roy of the Rovers stuff, Sending the goalkeeper the wrong way, Shooting boots, Sleeping giants, Slide rule pass, Small matter of, Spiders web, Stayed hit, Steepling, Stinging the palms, Stonewall penalty, Straight off the training ground, Stramash, Taking one for the team, Team that likes to play football, Throw their cap on it, Thruppenny bit head / 50p head, Towering header, Two good feet, Turning into a basketball match, Turning into a cricket score, Usher/Shepherd the ball out of play, Walking a disciplinary tightrope, Wand of a left foot, We've got a cup tie on our hands, Winger in their pocket, Wrap foot around it, Your De Bruynes, your Gundogans etc.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels.   Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said.   “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.”   Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.   https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas.   The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/     XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay     XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition.   G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment.   The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes.   "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes.   The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting  it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems.   https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.).   – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. ​This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November.   ​ https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/   XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. ,   The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say.   In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries."   The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours.   Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy.   At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy.   Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells.   Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially.   Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells.   “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release.   “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy   XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification

Why do so many of us struggle in relationships?Clinical psychologist and author Phoebe Rogers joins me to unpack the hidden roots of relationship patterns - from shame and self-sacrifice to the fine line between support and codependency. We explore why awareness alone isn't enough, how to build safety and self-soothing into your life, and the role of inner child work in breaking free from old cycles. Phoebe also shares insights on ADHD, attachment, and navigating modern dating, offering practical tools to create healthier love and connection.TOPICS:Shame and self-soothing as foundations for healthy relationshipsCodependency vs. supportive partnership patternsADHD, attachment styles, and modern dating dynamicsMORE FROM NICK:Book a FREE call here to learn about the Move Your Mind Program: https://tinyurl.com/yc3zmu35Find all links here: https://nickbracks.start.page/Sign up to the website: nickbracks.comConnect with Nick on Instagram, Twitter & LinkedInMORE FROM PHEOBE: https://www.therelationshipspace.com.au/ Hosted on Acast. See acast.com/privacy for more information.

The Neoliberal Round Podcast by Renaldo McKenzieEpisode Script: “Faith, Film, and the Future Featuring Abria Jackson”Creator/Host: Renaldo C. McKenzie[Intro]Hello everyone, and welcome to another episode of The Neoliberal Round Podcast. I'm your host, Rev. Renaldo McKenzie.Today, I'm honored to sit with the dynamic, ever-charming, and deeply talented Abria Jackson—an actress, mentor, and graduate student whose career and calling blend art, faith, and service.Abria recently starred in Night of Violence, which opened at the prestigious FrightFest in the UK. She traveled to London with her mother to witness the premiere, and we'll talk about that powerful experience. We'll also dive into her work on Law & Order: Organized Crime, her inspirations from Viola Davis and Halle Berry, her mentoring of young women, and her pursuit of a master's degree in Clinical and Counseling Psychology.[Segment 1 – The UK Premiere]Renaldo: What was it like, sitting in that London theater with your mom, watching your film open FrightFest?Abria: “It was very emotional. My father passed away a couple of years ago, and he was so supportive of my dream. Knowing my mom was in the audience reminded me that I have people who love me and support me. I also felt like my dad was there, watching from heaven. My mom was cheering, even when no one else was, and people around her were cracking up—it was unforgettable.”Renaldo: What did it mean personally to have her there?Abria: “It felt full circle. God was reminding me to keep going, that I'm on the right path. The fact that my mom was alive and present for that moment—it meant everything.”[Segment 2 – Acting as Healing]Renaldo: You mentioned Catwoman, a Black rock star, and Tanya from Mortal Kombat as dream roles. Why those?Abria: “All three connect directly to my childhood. They'd heal my inner child. Acting was more than entertainment—it was spiritual. Growing up, life wasn't always glitter and rainbows. Acting gave me an outlet, and now keeping that inner child alive helps me bring truth to every role.”[Segment 3 – Balancing Faith, Career, and Self-Care]Renaldo: How do you balance school, career, and everything else?Abria: “I'm very intentional with my time. I write everything in my planner and make sure I hit my goals. But I also remind myself that you can't pour from an empty cup. Self-care matters. For me, that's $5 Tuesdays at the movies—it's my reset.”Renaldo: And your faith?Abria: “Faith keeps me going. My mom once bought a name meaning that said Aabria means faith. That's my story. When auditions don't come, when money's tight—faith carries me.”[Segment 4 – Mentorship & Psychology]Renaldo: Beyond acting, you're also co-leading a mentorship group for teen girls and pursuing a master's in counseling. What inspired that?Abria: “Even in high school, people would come up to me and share their lives. It felt like a gift God placed in me. Now I want to perfect that gift—get licensed, gain knowledge, and help people in ways that blend spirituality and service.”[Segment 5 – Vision & Legacy]Renaldo: Looking ahead, what legacy do you want to build?Abria: “When God calls me home, I want people to say my life was an act of faith. Of course, I want roles that move people. But more than that, I want to be remembered as someone who served—who gave advice, helped people, and carried them through. What profits a person to gain the world but lose their soul? Character and service—that's the legacy I want.”[Closing]Abria Jackson is more than an actress—she is a storyteller, a servant, and a woman of faith. From Philly to London, from film sets to mentorship circles, her journey reminds us that art and service can walk hand in hand.You can follow Abria on Instagram at @itsabriajackson and on TikTok under her name.And stay tuned for her upcoming TV series Losing My Pride, expected in 2026.Thank you for listening to The Neoliberal Round Podcast. Until next time—walk good.

When supervision goes sideways, what's a pre-licensed therapist to do? In this candid conversation, Dr. Kate Walker and Jennifer Marie Fairchild pull back the curtain on one of the most anxiety-producing challenges facing associates and interns—addressing problematic supervision.Many therapists-in-training find themselves frozen when faced with supervision red flags, trapped between speaking up and risking their relationship with someone who holds power over their career. This episode offers practical, actionable strategies for having these difficult conversations with confidence and professionalism.We tackle the supervision power dynamic head-on, reminding associates that while these strategies empower you to advocate for yourself, the ultimate responsibility for a healthy supervision relationship lies with the supervisor. Learn how to document concerns, use "I" statements effectively, leverage your knowledge of state regulations, and bring solutions rather than just problems to the table.Perhaps most importantly, we address the boundary-setting that sometimes becomes necessary in problematic supervision relationships. From networking resources to supervision directories, we outline concrete options for associates who may need to transition to new supervision. The mental health field desperately needs dedicated new professionals—you're too important to lose because of discouraging supervision experiences.Whether you're currently experiencing supervision challenges or simply preparing yourself for potential future difficulties, this episode provides the roadmap and reassurance needed to navigate these waters with professionalism and self-advocacy. Remember that pushing back and developing your professional identity is a normal part of clinical development, not insubordination—and most supervisors genuinely want to support your growth when approached thoughtfully.Ready to transform your supervision experience? Listen now to gain the confidence to address concerns, set healthy boundaries, and continue your journey toward full licensure with renewed clarity and purpose.Get your step by step guide to private practice. Because you are too important to lose to not knowing the rules, going broke, burning out, and giving up. #counselorsdontquit.

Original Air Date: 10-18-2024Host: Jasmine T. Kency, M.D., Associate Professor of Internal Medicine and Pediatrics at the University of Mississippi Medical Center.Topic: New Clinical Developments - Recommended Colonoscopies, Cancer Screenings, Aspirin Intake, and MoreEmail the show: remedy@mpbonline.org. If you enjoy listening to this podcast, please consider contributing to MPB. https://donate.mpbfoundation.org/mspb/podcast. Hosted on Acast. See acast.com/privacy for more information.

This episode is a practical playbook for biotech job seekers and career climbers who want to interview with clarity, energy, and impact. Carina breaks down 25 common mistakes that quietly cost candidates offers, from rambling to over‑indexing on technical detail to skipping metrics. You'll learn how to answer the actual question asked, thread a positive through‑line across job changes, balance “I” and “we,” and anchor answers with outcomes and numbers. There's tactical guidance for recruiter screens and onsite loops, including how to read cues to be concise, translate jargon, and prepare questions that reveal culture, expectations, and first‑90‑day success metrics. If you're targeting roles across R&D, Quality, Clinical, or G&A in high‑growth biotechs, this episode will help you tighten your elevator pitch, signal motivation for the role and company, avoid negative framing, and follow up like a pro, so you leave every interviewer thinking you're the obvious next hire.Learn more about the Collaboratory Career Hub community and access our free resources:Join our Skool CommunityTake the Free 7-day Interview Sprint ChallengeCheck out our sister podcast: Building BiotechsSend Carina a connection request on LinkedIn!Stay connected with us:

Join the Behind the Knife Surgical Oncology Team as we discuss the nuances in the work up and management of patients with pheochromocytomas. Hosts: Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center. Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist/HPB surgeon at Kaiser LAMC in Los Angeles. Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a 2ndYear Surgical Oncology fellow at MD Anderson. Beth (Elizabeth) Barbera, MD (@elizcarpenter16) is a General Surgery physician in the United States Air Force station at RAF Lakenheath. Joe (Joseph) Broderick, MD, MA (@joebrod5) is a General Surgery research resident between his second and third year at Brooke Army Medical Center. Galen Gist, MD (@gistgalen) is a General Surgery research resident between his second and third year at Brooke Army Medical Center. Learning Objectives: 1)    Review the presentation of patients with pheochromocytomas.  2)    Review the work up of patients with pheochromocytomas.  3)    Review the treatment of patients with pheochromocytomas.  4)    Review the surveillance of patients with pheochromocytomas.  References used in the making of this episode: Patel D. Surgical approach to patients with pheochromocytoma. Gland Surg. 2020;9(1):32-42. doi:10.21037/gs.2019.10.20. PMID: 32206597; PMCID:PMC7082266.   Eisenhofer G, Lenders JW, Siegert G, et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur J Cancer. 2012;48(11):1739-1749. doi:10.1016/j.ejca.2011.07.016. PMID:22036874; PMCID: PMC3372624.   Lenders JWM, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665-675. doi:10.1016/S0140-6736(05)67139-5.   Vicha A, Musil Z, Pacak K. Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Curr Opin Endocrinol Diabetes Obes. 2013;20(3):186-191. doi:10.1097/MED.0b013e32835fcc45. PMID: 23481210; PMCID: PMC4711348. https://pubmed.ncbi.nlm.nih.gov/23481210/ Dickson PV, Alex GC, Grubbs EG, et al. Posterior retroperitoneoscopic adrenalectomy is a safe and effective alternative to transabdominal laparoscopic adrenalectomy for pheochromocytoma. Surgery. 2011;150(3):452-458. doi:10.1016/j.surg.2011.07.004. https://pubmed.ncbi.nlm.nih.gov/21878230/ Lei K, Wang X, Yang Z, et al. Comparison of the retroperitoneal laparoscopic adrenalectomy versus transperitoneal laparoscopic adrenalectomy for large (≥6 cm) pheochromocytomas: a single-centre retrospective study. Front Oncol. 2023;13:1043753. doi:10.3389/fonc.2023.1043753. PMID: 36910608; PMCID: PMC9992891. https://pubmed.ncbi.nlm.nih.gov/36910608/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

ADHD affects more than 7 million children in the U.S., with many experiencing moderate to severe symptoms; yet nearly a third receive no treatment, highlighting the need for broader, integrative solutions Research shows children with ADHD are more likely to have magnesium deficiency, which disrupts neurotransmitters, stress response, and brain signaling. This worsens hyperactivity, impulsivity, inattention, and emotional instability Clinical trials demonstrate magnesium supplementation improves behavior, focus, and social interactions in children with ADHD, with the strongest benefits observed in those correcting underlying magnesium deficiencies Food alone is often not enough to restore optimal magnesium levels due to soil depletion and poor absorption. Supplementation with forms like glycinate, malate, or L-threonate is a valuable tool Environmental and lifestyle strategies, like reducing pesticide and chemical exposure and improving gut health, help manage or reduce ADHD symptoms naturally

Kaylin and Sharmin were joined by UCLA Cardiology fellows, Drs. Rachel Ohman and Angela Duvalyan, to discuss a case of a 49 year old woman with acute chest pain. Angela Duvalyan, MD is a second year Cardiology Fellow at University of California, Los Angeles (UCLA). Her clinical interests include interventional cardiology, medical education, and clinical… Read More »Episode 422: WDx #38: Clinical Unknown with UCLA Cardiology fellows

So many PAs reach out to me asking about how to transition from a clinical career to non-clinical. There are lots of options and pathways out there, and today I'm excited to have my dear friend, Courtney Titus, share her story of creating her own non-clinical career. Courtney is a Pediatric ER PA turned Director of a Pediatric Clinical Pathways program that she built herself! Tune into today's episode as Courtney shares the nitty gritty on how she created a non-clinical career. She keeps it real by sharing both the good and the bad of building her current role. Stay tuned to the end of the episode where Courtney shares actionable tips on how other PAs can also move into non-clinical careers. My biggest takeaway from today's conversation with Courtney - follow the path of joy. What brings you joy and fulfillment, both personally and professionally? Get crystal clear on that vision and then you can create your own pathway to achieve that joy.SPONSORS

Send us a textWill Van Derveer, MD is a leader in the adoption of integrative psychiatry practices globally. After discovering that his conventional psychiatric training was inadequate to answer many of the challenges facing his patients, Dr. Van Derveer began to learn how to resolve the root causes of common psychiatric problems such as depression, anxiety, and insomnia.

In this solo episode of Modern Chiropractic Mastery, Dr. Kevin Christie discusses the concept of clinical capacity blocks, a common issue faced by chiropractic practices that have reached their maximum patient load. The episode outlines several factors contributing to clinical capacity blocks, such as lack of support team members, insufficient clinical duplication, inadequate space, poor mindset, and issues with profit and cash flow. Listeners will learn actionable strategies to overcome various capacity blocks and optimize their practice growth.

In this episode, Dr. Sausha and Dr. Mark McCawley explore the revolutionary role of Nd:YAG lasers in modern periodontal therapy. They trace the evolution of laser technology, discuss compelling research backing its effectiveness, and share real-world clinical experiences that showcase its benefits for patient outcomes. The discussion also clears up common myths about dental lasers, looks ahead to the future of dental innovation, and underscores the importance of embracing advanced technologies in clinical practice. Both doctors advocate for continuous education and adaptability as essential tools for success in the ever-changing landscape of dentistry.

Published October 2, 2025 In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, discuss the latest developments in self-collection testing for women's health and beyond. Together, they explore:New podcast format launching (00:01): Dr. Pritt previews exciting changes coming to “Answers From the Lab.” Emerging self-collection tests (01:21): Explore the growing range of self-collection tests now available for use in both clinical settings and at home.Validation of self-collection tests (03:19): Learn how laboratorians validated recent self- and home-collection tests to ensure quality and accuracy. Benefits for patients and public health (06:56): Understand the benefits self-collection tests offer to patients and how the tests impact public health.Limitations and implementation considerations (08:23): Review key factors to consider when incorporating self-collection testing into clinical care.Future innovation (11:34): Insights into where self-collection testing may evolve in the years ahead.

When an allergic flare strikes, fast and effective relief is critical—not just for patient comfort but to prevent chronic skin damage and infection as well. In this podcast episode, dermatology specialist Dr. Joya Griffin dives into how to diagnose the source of pruritus, how to choose between starting symptomatic treatment or performing additional diagnostics, and how to integrate Janus kinase (JAK) inhibitors into the multimodal management of allergic disease in dogs. Sponsored by Elanco Contact us:Podcast@instinct.vetWhere to find us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/X: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostSarah Pate - Producer & Project Manager, Brief StudioTaylor Argo - Podcast Production & Sound Editing INDICATIONSZenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.IMPORTANT SAFETY INFORMATIONRead the entire package insert before using this drug, including the Boxed Warning. For full prescribing information call 1-888-545-5973 or visit http://www.elancolabels.com/us/zenrelia WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.

This episode of The Neoliberal Round Podcast features the dynamic Abria Jackson, actress, mentor, and graduate student, in conversation with Rev. Renaldo McKenzie.Fresh off her UK premiere at FrightFest for Night of Violence, Abria talks about bringing her mom to London for the milestone, her inspirations from Viola Davis and Halle Berry, and how faith keeps her grounded as she balances acting, mentorship, and graduate studies in Clinical and Counseling Psychology.✨ Premieres Friday at 6PM on The Neoliberal Round YouTube Channel and across all podcast platforms.

Do you know about these alternatives to traditional microscopic loupes? Bethany Montoya, RDH, shares three types of magnification technology you don't need to see to believe in their effectiveness. Bethany Montoya, MBA, RDH Read by Jackie Sanders  https://www.rdhmag.com/patient-care/article/55301287/clinical-tips-periodontal-microscopy-and-endoscopy

From ESCV 2025, Vincent speaks with Elke Wollants about a project to identify SARS-CoV-2 and other viruses in toilet waste from airplanes. Host: Vincent Racaniello Guest: Elke Wollants Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Laboratory for Clinical and Epidemiological Virology (KU Leuven) Virologists in Greece (TWiV 1255 from ESCV) Airplane wastewater surveillance for pathogens (SSRN) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

Episode 51 - Clinicians Driving Interoperability: Insights from the HL7 Da Vinci Project Clinical Advisory Council (CAC) On this episode POCP CEO and host Tony Schueth sat down with Dr. Julia Skapik (SVP & CMO at PurpleLab, practicing physician, member of the HL7 Da Vinci Clinical Advisory Council, and outgoing HL7 International board chair) and Dr. Steven Waldron (Chief Medical Informatics Officer at the American Academy of Family Physicians and Co-Chair of the Da Vinci Clinical Advisory Council). Together, they explored how clinicians are shaping interoperability and standards development through the HL7 Da Vinci Project's Clinical Advisory Council (CAC).

Functional movement disorders are a common clinical concern for neurologists. The principle of “rule-in” diagnosis, which involves demonstrating the difference between voluntary and automatic movement, can be carried through to explanation, triage, and evidence-based multidisciplinary rehabilitation therapy. In this episode, Gordon Smith, MD, FAAN speaks Jon Stone, PhD, MB, ChB, FRCP, an author of the article “Multidisciplinary Treatment for Functional Movement Disorder” in the Continuum® August 2025 Movement Disorders issue. Dr. Smith is a Continuum® Audio interviewer and a professor and chair of neurology at Kenneth and Dianne Wright Distinguished Chair in Clinical and Translational Research at Virginia Commonwealth University in Richmond, Virginia. Dr. Stone is a consultant neurologist and honorary professor of neurology at the Centre for Clinical Brain Sciences at the University of Edinburgh in Edinburgh, United Kingdom. Additional Resources Read the article: Multidisciplinary Treatment for Functional Movement Disorder Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @gordonsmithMD Guest: @jonstoneneuro Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. This exclusive Continuum Audio interview is available only to you, our subscribers. We hope you enjoy it. Thank you for listening. Dr Smith: Hello, this is Dr Gordon Smith. Today I've got the great pleasure of interviewing Dr Johnstone about his article on the multidisciplinary treatment for functional neurologic disorder, which he wrote with Dr Alan Carson. This article will appear in the August 2025 Continuum issue on movement disorders. I will say, Jon, that as a Continuum Audio interviewer, I usually take the interviews that come my way, and I'm happy about it. I learn something every time. They're all a lot of fun. But there have been two instances where I go out and actively seek to interview someone, and you are one of them. So, I'm super excited that they allowed me to talk with you today. For those of our listeners who understand or are familiar with FND, Dr Stone is a true luminary and a leader in this, both in clinical care and research. He's also a true humanist. And I have a bit of a bias here, but he was the first awardee of the Ted Burns Humanism in Neurology award, which is a real honor and reflective of your great work. So welcome to the podcast, Jon. Maybe you can introduce yourself to our audience. Dr Stone: Well, thank you so much, Gordon. It was such a pleasure to get that award, the Ted Burns Award, because Ted was such a great character. I think the spirit of his podcasts is seen in the spirit of these podcasts as well. So, I'm a neurologist in Edinburgh in Scotland. I'm from England originally. I'm very much a general neurologist still. I still work full-time. I do general neurology, acute neurology, and I do two FND clinics a week. I have a research group with Alan Carson, who you mentioned; a very clinical research group, and we've been doing that for about 25 years. Dr Smith: I really want to hear more about your clinical approach and how you run the clinic, but I wonder if it would be helpful for you to maybe provide a definition. What's the definition of a functional movement disorder? I mean, I think all of us see these patients, but it's actually nice to have a definition. Dr Stone: You know, that's one of the hardest things to do in any paper on FND. And I'm involved with the FND society, and we're trying to get together a definition. It's very hard to get an overarching definition. But from a movement disorder point of view, I think you're looking at a disorder where there is an impairment of voluntary movement, where you can demonstrate that there is an automatic movement, which is normal in the same movement. I mean, that's a very clumsy way of saying it. Ultimately, it's a disorder that's defined by the clinical features it has; a bit like saying, what is migraine? You know? Or, what is MS? You know, it's very hard to actually say that in a sentence. I think these are disorders of brain function at a very broad level, and particularly with FND disorders, of a sort of higher control of voluntary movement, I would say. Dr Smith: There's so many pearls in this article and others that you've written. One that I really like is that this isn't a diagnosis of exclusion, that this is an affirmative diagnosis that have clear diagnostic signs. And I wonder if you can talk a little bit about the diagnostic process, arriving at an FND diagnosis for a patient. Dr Stone: I think this is probably the most important sort of “switch-around” in the last fifteen, twenty years since I've been involved. It's not new information. You know, all of these diagnostic signs were well known in the 19th century; and in fact, many of them were described then as well. But they were kind of lost knowledge, so that by the time we got to the late nineties, this area---which was called conversion disorder then---it was written down. This is a diagnosis of exclusion that you make when you've ruled everything out. But in fact, we have lots of rule in signs, which I hope most listeners are familiar with. So, if you've got someone with a functional tremor, you would do a tremor entrainment test where you do rhythmic movements of your thumb and forefinger, ask the patient to copy them. It's very important that they copy you rather than make their own movements. And see if their tremor stops briefly, or perhaps entrains to the same rhythm that you're making, or perhaps they just can't make the movement. That might be one example. There's many examples for limb weakness and dystonia. There's a whole lot of stuff to learn there, basically, clinical skills. Dr Smith: You make a really interesting point early on in your article about the importance of the neurological assessment as part of the treatment of the patient. I wonder if you could talk to our listeners about that. Dr Stone: So, I think, you know, there's a perception that- certainly, there was a perception that that the neurologist is there to make a diagnosis. When I was training, the neurologist was there to tell the patient that they didn't have the kind of neurological problem and to go somewhere else. But in fact, that treatment process, when it goes well, I think begins from the moment you greet the patient in the waiting room, shake their hand, look at them. Things like asking the patient about all their symptoms, being the first doctor who's ever been interested in their, you know, horrendous exhaustion or their dizziness. You know, questions that many patients are aware that doctors often aren't very interested in. These are therapeutic opportunities, you know, as well as just taking the history that enable the patient to feel relaxed. They start thinking, oh, this person's actually interested in me. They're more likely to listen to what you've got to say if they get that feeling off you. So, I'd spend a lot of time going through physical symptoms. I go through time asking the patient what they do, and the patients will often tell you what they don't do. They say, I used to do this, I used to go running. Okay, you need to know that, but what do they actually do? Because that's such valuable information for their treatment plan. You know, they list a whole lot of TV shows that they really enjoy, they're probably not depressed. So that's kind of useful information. I also spend a lot of time talking to them about what they think is wrong. Be careful, that they can annoy patients, you know. Well, I've come to you because you're going to tell me what's wrong. But what sort of ideas had you had about what was wrong? I need to know so that I can deal with those ideas that you've had. Is there a particular reason that you're in my clinic today? Were you sent here? Was it your idea? Are there particular treatments that you think would really help you? These all set the scene for what's going to come later in terms of your explanation. And, more importantly, your triaging of the patient. Is this somebody where it's the right time to be embarking on treatment, which is a question we don't always ask yourself, I think. Dr Smith: That's a really great point and kind of segues to my next question, which is- you talked a little bit about this, right? Generally speaking, we have come up with this is a likely diagnosis earlier, midway through the encounter. And you talked a little bit about how to frame the encounter, knowing what's coming up. And then what's coming up is sharing with the patient our opinion. In your article, you point out this should be no different than telling someone they have Parkinson's disease, for instance. What pearls do you have and what pitfalls do you have in how to give the diagnosis? And, you know, a lot of us really weren't trained to do this. What's the right way, and what are the most common land mines that folks step on when they're trying to share this information with patients? Dr Stone: I've been thinking about this for a long time, and I've come to the conclusion that all we need to do with this disorder is stop being weird. What goes wrong? The main pitfall is that people think, oh God, this is FND, this is something a bit weird. It's in a different box to all of the other things and I have to do something weird. And people end up blurting out things like, well, your scan was normal or, you haven't got epilepsy or, you haven't got Parkinson's disease. That's not what you normally do. It's weird. What you normally do is you take a deep breath and you say, I'm sorry to tell you've got Parkinson's disease or, you have this type of dystonia. That's what you normally say. If you follow the normal- what goes wrong is that people don't follow the normal rules. The patient picks up on this. What's going on here? This doctor's telling me what I don't have and then they're starting to talk about some reason why I've got this, like stress, even though I don't- haven't been told what it is yet. You do the normal rules, give it a name, a name that you're comfortable with, preferably as specific as possible: functional tremor, functional dystonia. And then do what you normally do, which is explain to the patient why you think it's this. So, if someone's got Parkinson's, you say, I think you've got Parkinson's because I noticed that you're walking very slowly and you've got a tremor. And these are typical features of Parkinson. And so, you're talking about the features. This is where I think it's the most useful thing that you can do. And the thing that I do when it goes really well and it's gone badly somewhere else, the thing I probably do best, what was most useful, is showing the patient their signs. I don't know if you do that, Gordon, but it's maybe not something that we're used to doing. Dr Smith: Wait, maybe you can talk more about that, and maybe, perhaps, give an example? Talk about how that impacts treatment. I was really impressed about the approach to physical therapy, and treatment of patients really leverages the physical examination findings that we're all well-trained to look for. So maybe explore that a little bit. Dr Stone: Yeah, I think absolutely it does. And I think we've been evolving these thoughts over the last ten or fifteen years. But I started, you know, maybe about twenty years ago, started to show people their tremor entrainment tests. Or their Hoover sign, for example; if you don't know Hoover sign, weakness of hip extension, that comes back to normal when the person's flexing their normal leg, their normal hip. These are sort of diagnostic tricks that we had. Ahen I started writing articles about FND, various senior neurologists said to me, are you sure you should write this stuff down? Patients will find out. I wrote an article with Marc Edwards called “Trick or Treat in Neurology” about fifteen years ago to say that actually, although they're they might seem like tricks, there really are treats for patients because you're bringing the diagnosis into the clinic room. It's not about the normal scan. You can have FND and MS. It's not about the normal scan. It's about what you're seeing in front of you. If you show that patient, yes, you can't move your leg. The more you try, the worse it gets. I can see that. But look, lift up your other leg. Let me show you. Can you see now how strong your leg is? It's such a powerful way of communicating to the patient what's wrong with them diagnostically, giving them that confidence. What it's also doing is showing them the potential for improvement. It's giving them some hope, which they badly need. And, as we'll perhaps talk about, the physio treatment uses that as well because we have to use a different kind of physio for many forms of functional movement disorder, which relies on just glimpsing these little moments of normal function and promoting them, promoting the automatic movement, squashing down that abnormal pattern of voluntary movement that people have got with FND. Dr Smith: So, maybe we can talk about that now. You know, I've got a bunch of other questions to ask you about mechanism and stuff, but let's talk about the approach to physical therapy because it's such a good lead-in and I always worry that our physical therapists aren't knowledgeable about this. So, maybe some examples, you have some really great ones in the article. And then words of wisdom for us as we're engaging physical therapists who may not be familiar with FND, how to kind of build that competency and relationship with the therapist with whom you work. Dr Stone: Some of the stuff is the same. Some of the rehabilitation ideas are similar, thinking about boom and bust activity, which is very common in these patients, or grading activity. That's similar, but some of them are really different. So, if you have a patient with a stroke, the physiotherapist might be very used to getting that person to think and look at their leg to try and help them move, which is part of their rehabilitation. In FND, that makes things worse. That's what's happening in Hoover sign and tremor entrainment sign. Attention towards the limb is making it worse. But if the patient's on board with the diagnosis and understands it, they'll also see what you need to do, then, in the physio is actively use distraction in a very transparent way and say to the patient, look, I think if I get you to do that movement, and I'll film you, I think your movement's going to look better. Wouldn't that be great if we could demonstrate that? And the patient says, yeah, that would be great. We're kind of actively using distraction. We're doing things that would seem a bit strange for someone with other forms of movement disorder. So, the patients, for example, with functional gait disorders who you discover can jog quite well on a treadmill. In fact, that's another diagnostic test. Or they can walk backwards, or they can dance or pretend that they're ice skating, and they have much more fluid movements because their ice skating program in their brain is not corrupted, but their normal walking program is. So, can you then turn ice skating or jogging into normal walking? It's not that complicated, I think. The basic ideas are pretty simple, but it does require some creativity from whoever's doing the therapy because you have to use what the patient's into. So, if the patient used to be a dancer- we had a patient who was a, she was really into ballet dancing. Her ballet was great, but her walking was terrible. So, they used ballet to help her walk again. And that's incredibly satisfying for the therapist as well. So, if you have a therapist who's not sure, there are consensus recommendations. There are videos. One really good success often makes a therapist want to do that again and think, oh, that's interesting. I really helped that patient get better. Dr Smith: For a long time, this has been framed as a mental health issue, conversion disorder, and maybe we can talk a little bit about early life of trauma as a risk factor. But, you know, listening to you talk, it sounds like a brain network problem. Even the word “functional”, to me, it seems a little judgmental. I don't know if this is the best term, but is this really a network problem? Dr Stone: The word “functional”, for most neurologists, sounds judgmental because of what you associate it with. If you think about what the word actually is, it's- it does what it says on the tin. There's a disordered brain function. I mean, it's not a great word. It's the least worst term, in my view. And yes, of course it's a brain network problem, because what other organ is it going to be? You know, that's gone wrong? When software brains go wrong, they go wrong in networks. But I think we have to be careful not to swing that pendulum too far to the other side because the problem here, when we say asking the question, is this a mental health problem or a neurological one, we're just asking the wrong question. We're asking a question that makes no sense. However you try and answer that, you're going to get a stupid answer because the question doesn't make sense. We shouldn't have those categories. It's one organ. And what's so fascinating about FND---and I hope what can incite your sort of curiosity about it---is this disorder which defies this categorization. You see some patients with it, they say, oh, they've got a brain network disorder. Then you meet another patient who was sexually abused for five years by their uncle when they were nine, between nine and fourteen; they developed an incredibly strong dissociative threat response into that experience. They have crippling anxiety, PTSD, interpersonal problems, and their FND is sort of somehow a part of that; part of that experience that they've had. So, to ignore that or to deny or dismiss psychological, psychiatric aspects, is just as bad and just as much a mistake as to dismiss the kind of neurological aspects as well. Dr Smith: I wonder if this would be a good time to go back and talk a little bit about a concept that I found really interesting, and that is FND as a prodromal syndrome before a different neurological problem. So, for instance, FND prodromal to Parkinson's disease. Can you talk to us a little bit about that? I mean, obviously I was familiar with the fact that patients who have nonepileptic seizurelike events often have epileptic seizures, but the idea of FND ahead of Parkinson's was new to me. Dr Stone: So, this is definitely a thing that happens. It's interesting because previously, perhaps, if you saw someone who was referred with a functional tremor---this has happened to me and my colleagues. They send me some with a functional tremor. By the time I see them, it's obvious they've got Parkinson's because it's been a little gap. But it turns out that the diagnosis of functional tremor was wrong. It was just that they've developed that in the prodrome of Parkinson's disease. And if you think about it, it's what you'd expect, really, especially with Parkinson's disease. We know people develop anxiety in the prodrome of Parkinson's for ten, fifteen years before it's part of the prodrome. Anxiety is a very strong risk factor for FND, and they're already developing abnormalities in their brain predisposing them to tremor. So, you put those two things together, why wouldn't people get FND? It is interesting to think about how that's the opposite of seizures, because most people with comorbidity of functional seizures and epilepsy, 99% of the time the epilepsy came first. They had the experience of an epileptic seizure, which is frightening, which evokes strong threat response and has somehow then led to a recapitulation of that experience in a functional seizure. So yeah, it's really interesting how these disorders overlap. We're seeing something similar in early MS where, I think, there's a slight excess of functional symptoms; but as the disease progresses, they often become less, actually. Dr Smith: What is the prognosis with the types of physical therapy? And we haven't really talked about psychological therapy, but what's the success rate? And then what's the relapse rate or risk? Dr Stone: Well, it does depend who they're seeing, because I think---as you said---you're finding difficult to get people in your institution who you feel are comfortable with this. Well, that's a real problem. You know, you want your therapists to know about this condition, so that matters. But I think with a team with a multidisciplinary approach, which might include psychological therapy, physio, OT, I think the message is you can get really good outcomes. You don't want to oversell this to patients, because these treatments are not that good yet. You can get spectacular outcomes. And of course, people always show the videos of those. But in published studies, what you're seeing is that most studies of- case series of rehabilitation, people generally improve. And I think it's reasonable to say to a patient, that we have these treatments, there's a good chance it's going to help you. I can't guarantee it's going to help you. It's going to take a lot of work and this is something we have to do together. So, this is not something you're going to do to the patient, they're going to do it with you. Which is why it's so important to find out, hey, do they agree with you with the diagnosis? And check they do. And is it the right time? It's like when someone needs to lose weight or change any sort of behavior that they've just become ingrained. It's not easy to do. So, I don't know if that helps answer the question. Dr Smith: No, that's great. And you actually got right where I was wanting to go next, which is the idea of timing and acceptance. You brought this up earlier on, right? So, sometimes patients are excited and accepting of having an affirmative diagnosis, but sometimes there's some resistance. How do you manage the situation where you're making this diagnosis, but a patient's resistant to it? Maybe they're fixating on a different disease they think they have, or for whatever reason. How do you handle that in terms of initiating therapy of the overall diagnostic process? Dr Stone: We should, you know, respect people's rights to have whatever views they want about what's wrong with them. And I don't see my job as- I'm not there to change everyone's mind, but I think my job is to present the information to them in a kind of neutral way and say, look, here it is. This is what I think. My experience is, if you do that, most people are willing to listen. There are a few who are not, but most people are. And most of the time when it goes wrong, I have to say it's us and not the patients. But I think you do need to find out if they can have some hope. You can't do rehabilitation without hope, really. That's what you're looking for. I sometimes say to patients, where are you at with this? You know, I know this is a really hard thing to get your head around, you've never heard of it before. It's your own brain going wrong. I know that's weird. How much do you agree with it on a scale of naught to ten? Are you ten like completely agreeing, zero definitely don't? I might say, are you about a three? You know, just to make it easy for them to say, no, I really don't agree with you. Patients are often reluctant to tell you exactly what they're thinking. So, make it easy for them to disagree and then see where they're at. If they're about seven, say, that's good. But you know, it'd be great if you were nine or ten because this is going to be hard. It's painful and difficult, and you need to know that you're not damaging your body. Those sort of conversations are helpful. And even more importantly, is it the right time? Because again, if you explore that with people, if a single mother with four kids and, you know, huge debts and- you know, it's going to be very difficult for them to engage with rehab. So, you have to be realistic about whether it's the right time, too; but keep that hope going regardless. Dr Smith: So, Jon, there's so many things I want to talk to you about, but maybe rather than let me drive it, let me ask you, what's the most important thing that our listeners need to know that I haven't asked you about? Dr Stone: Oh God. I think when people come and visit me, they sometimes, let's go and see this guy who does a lot of FND, and surely, it'll be so easy for him, you know? And I think some of the feedback I've had from visitors is, it's been helpful to watch, to see that it's difficult for me too. You know, this is quite hard work. Patients have lots of things to talk about. Often you don't have enough time to do it in. It's a complicated scenario that you're unravelling. So, it's okay if you find it difficult work. Personally, I think it's very rewarding work, and it's worth doing. It's worth spending the time. I think you only need to have a few patients where they've improved. And sometimes that encounter with the neurologist made a huge difference. Think about whether that is worth it. You know, if you do that with five patients and one or two of them have that amazing, really good response, well, that's probably worth it. It's worth getting out of bed in the morning. I think reflecting on, is this something you want to do and put time and effort into, is worthwhile because I recognize it is challenging at times, and that's okay. Dr Smith: That's a great number needed to treat, five or six. Dr Stone: Exactly. I think it's probably less than that, but… Dr Smith: You're being conservative. Dr Stone: I think deliberately pessimistic; but I think it's more like two or three, yeah. Dr Smith: Let me ask one other question. There's so much more for our listeners in the article. This should be required reading, in my opinion. I think that of most Continuum, but this, I really truly mean it. But I think you've probably inspired a lot of listeners, right? What's the next step? We have a general or comprehensive neurologist working in a community practice who's inspired and wants to engage in the proactive care of the FND patients they see. What's the next step or advice you have for them as they embark on this? It strikes me, like- and I think you said this in the article, it's hard work and it's hard to do by yourself. So, what's the advice for someone to kind of get started? Dr Stone: Yeah, find some friends pretty quick. Though, yeah, your own enthusiasm can take you a long way, you know, especially with we've got much better resources than we have. But it can only take you so far. It's really particularly important, I think, to find somebody, a psychiatrist or psychologist, you can share patients with and have help with. In Edinburgh, that's been very important. I've done all this work with the neuropsychiatrist, Alan Carson. It might be difficult to do that, but just find someone, send them an easy patient, talk to them, teach them some of this stuff about how to manage FND. It turns out it's not that different to what they're already doing. You know, the management of functional seizures, for example, is- or episodic functional movement disorders is very close to managing panic disorder in terms of the principles. If you know a bit about that, you can encourage people around you. And then therapists just love seeing these patients. So, yeah, you can build up slowly, but don't- try not to do it all on your own, I would say. There's a risk of burnout there. Dr Smith: Well, Dr Stone, thank you. You don't disappoint. This has really been a fantastic conversation. I really very much appreciate it. Dr Stone: That's great, Gordon. Thanks so much for your time, yeah. Dr Smith: Well, listeners, again, today I've had the great pleasure of interviewing Dr Jon Stone about his article on the multidisciplinary treatment for functional neurologic disorder, which he wrote with Dr Alan Carson. This article appears in the August 2025 Continuum issue on movement disorders. Please be sure to check out Continuum Audio episodes from this and other issues. And listeners, thank you once again for joining us today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. We hope you've enjoyed this subscriber-exclusive interview. Thank you for listening.

SUMMARY In this episode of Vibe Science, Ryan Alford interviews Dr. Paramesh Gopi, co-founder of Sound Health. Dr. Paramesh Gopi shares his journey from tech entrepreneur to doctor, and discusses the development of the Sono Band—a wearable device using AI-powered, personalized sound and vibration therapy to clear nasal congestion and improve sleep. The episode covers clinical results, FDA clearance, and new research on sleep improvement, as well as upcoming products and applications in airway health. Listeners learn how innovative technology is transforming wellness through better breathing, sleep, and overall performance.   TAKEAWAYS Personal health journey of Dr. Paramesh Gopi and its impact on his work. Development of Sound Health and the Sono Band wearable device. Use of AI and machine learning to create personalized sound and vibration therapy. Mechanism of action: how sound and vibration clear nasal congestion. Clinical evidence supporting the effectiveness of the Sono Band. FDA clearance process and clinical trials for the device. Broader applications of the technology for sleep improvement and overall wellness. Future product developments, including a focus on sleep and airway health. Importance of non-invasive, drug-free alternatives for treating nasal congestion and related issues. Interconnectedness of breathing, sleeping, and overall health performance. This episode is sponsored by: Warrior Salt Electrolyte Powder – Hydrate & Reenergize Naturally Experience Warrior Salt's all-natural electrolyte powder for optimal hydration and performance. Boost energy, prevent cramps, and stay hydrated. Order Now!  

Pedro e João discutem intoxicação por metanol, em meio ao surto de casos atual. Panorama do surto atual, outros casos no Brasil, sinais clínicos, diagnóstico e tratamento são abordados nesse episódio.Referências:1. https://methanolpoisoning.msf.org/wp-content/uploads/2023/03/MSF_International_Methanol-Poisoning_Protocol_v2_20230110_EN.pdf2. https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/notas-tecnicas/2025/nota-tecnica-conjunta-no-360-2025-dvsat-svsa-ms.pdf3. Roberts, Darren M et al. “Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement.” Critical care medicine vol. 43,2 (2015): 461-72. doi:10.1097/CCM.00000000000007084. Kraut, Jeffrey A, and Michael E Mullins. “Toxic Alcohols.” The New England journal of medicine vol. 378,3 (2018): 270-280. doi:10.1056/NEJMra16152955. Kraut, Jeffrey A. “Approach to the Treatment of Methanol Intoxication.” American journal of kidney diseases : the official journal of the National Kidney Foundation vol. 68,1 (2016): 161-7. doi:10.1053/j.ajkd.2016.02.0586. Barceloux, Donald G et al. “American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning.” Journal of toxicology. Clinical toxicology vol. 40,4 (2002): 415-46. doi:10.1081/clt-1200067457. Souza FGT e, Nogueira VVE, Maynart LI, Oliveira RL de, Mendonça TC dos S, Oliveira PD. Neuropatia óptica tóxica por inalação de metanol. Rev brasoftalmol [Internet]. 2018Jan;77(1):47–9. Available from: https://doi.org/10.5935/0034-7280.201800108. https://www.gov.br/mj/pt-br/assuntos/noticias/nota-oficial-2014-governo-federal-estabelece-protocolo-de-acao-diante-de-intoxicacoes-por-metanol9. https://emcrit.org/ibcc/alcohols/10. Anyfantakis, D et al. “Ruling in the diagnosis of methanol intoxication in a young heavy drinker: a case report.” Journal of medicine and life vol. 5,3 (2012): 332-4.

Ashkan returns to reveal how Southcliffe Dental transformed from near-bankruptcy to unprecedented profitability through a revolutionary therapist-led model. From losing half his body weight to facing GDC proceedings, he opens up about the personal costs of rapid expansion and the dark period when £4 million in clawbacks nearly destroyed everything. His ex-wife's intervention during his lowest moment becomes a turning point, leading to a complete business overhaul that's now attracting attention from private equity firms across the sector. Raw, unfiltered, and brutally honest about the realities of corporate dental leadership.In This Episode00:01:25 - Quality over quantity mindset shift00:02:50 - The £4 million clawback crisis00:06:00 - Revolutionary therapist business model00:17:35 - Organisational restructure and delegation00:25:30 - Leadership philosophy and high standards00:30:50 - Physical transformation journey00:46:45 - GDC proceedings and workplace allegations01:04:25 - Blackbox thinking01:17:05 - Clinical errors and patient management01:23:15 - Business decisions and banking relationships01:33:15 - Fantasy dinner party01:08:45 - Last days and legacyAbout Ashkan PitchforthAshkan is the CEO and co-founder of Southcliffe Dental Group, which operates 24 mixed NHS practices employing around 400 people. He pioneered an innovative therapist-led delivery model that has revolutionised the group's profitability, taking EBITDA from zero to 7-8 million within two years. A clinical dentist turned entrepreneur, he's known for his direct leadership style and willingness to challenge conventional dental business models.

In this throwback episode Zach and Kevin feature Dr. Bob Convissar, a pioneer in laser dentistry with over 32 years of experience. He's a prolific author, lecturer, and practitioner who began his career after graduating from NYU in 1980 and acquiring a unique, century-old dental practice in New York City The main topic is the ABC's of Laser Dentistry, starting with a critical distinction between true lasers (like CO2​ and Erbium) and devices often called lasers but primarily used as hot glass tips (like diodes). Bob explains that diodes, which can operate at extremely high temperatures (750∘C to 1500∘C), work thermally, creating a burn, while CO2​ and Erbium lasers are absorbed by the water in soft tissue and vaporize it at 100∘C. He emphasizes that the CO2​ laser is the best option for general dentists doing soft tissue work, as it creates a much smaller zone of necrosis (thermal damage) than ElectroSurge or diode lasers, leading to better healing. He also offers a crucial financial perspective, arguing that while a CO2​ laser may have a higher initial purchase price (around $30,000), its lack of expensive disposable tips makes it a more cost-effective long-term investment than a cheaper diode laser (like a Picasso) with high operating expenses (potentially $18,000 in tips per year). For a multi-faceted approach, he recommends dentists invest in a CO2​ laser, a modern air abrasion unit, and a Photobiomodulation (PBM) laser (around $2,000 to $3,000). PBM lasers are purely palliative and can be used for pain management, like treating TMJ issues or for analgesia on deciduous teeth, and for promoting healing after invasive procedures. Finally, Bob stresses that the most crucial factor in laser dentistry is training, advising listeners that any course focusing on only one manufacturer or wavelength is likely a sales pitch, not a comprehensive educational seminar. He promotes his widely used textbook, Principles and Practice of Laser Dentistry   Join the Very Dental Facebook group using the password "Timmerman," Hornbrook" or "McWethy," "Papa Randy," "Lipscomb" or "Gary!" The Very Dental Podcast network is and will remain free to download. If you'd like to support the shows you love at Very Dental then show a little love to the people that support us! -- Crazy Dental has everything you need from cotton rolls to equipment and everything in between and the best prices you'll find anywhere! If you head over to verydentalpodcast.com/crazy and use coupon code “VERYDENTAL10” you'll get another 10% off your order! Go save yourself some money and support the show all at the same time! -- The Wonderist Agency is basically a one stop shop for marketing your practice and your brand. From logo redesign to a full service marketing plan, the folks at Wonderist have you covered! Go check them out at verydentalpodcast.com/wonderist! -- Enova Illumination makes the very best in loupes and headlights, including their new ergonomic angled prism loupes! They also distribute loupe mounted cameras and even the amazing line of Zumax microscopes! If you want to help out the podcast while upping your magnification and headlight game, you need to head over to verydentalpodcast.com/enova to see their whole line of products! -- CAD-Ray offers the best service on a wide variety of digital scanners, printers, mills and even  their very own browser based design software, Clinux! CAD-Ray has been a huge supporter of the Very Dental Podcast Network and I can tell you that you'll get no better service on everything digital dentistry than the folks from CAD-Ray. Go check them out at verydentalpodcast.com/CADRay!      

How to Build Wealth as a Clinical Entrepreneur In this episode, Doc Danny Matta breaks down how your clinic can be more than just a job replacement—it can be your wealth-building engine. He shares five steps learned from mentors, mistakes, and over a decade of running businesses, showing how to reinvest in your practice, avoid costly tax-driven schemes, and keep your wealth strategy simple and sustainable. Quick Ask If you're finding value in the podcast, help us hit our mission of adding $1B in cash-based services to physical therapy. Share this episode with a clinician friend or post it to your IG stories and tag Danny—he'll reshare it! Episode Summary Core thesis: Your clinic is your best wealth-building asset. Treat it like the investment it is. Step 1: Stop investing outside the business at the start—double down on reinvesting in your practice until it grows. Step 2: Grow income to a level where you have more than you need, without falling into lifestyle creep. Step 3: Avoid tax-first investments; focus on solid opportunities first, with tax benefits as a bonus. Step 4: Keep outside investments simple, liquid, and automated (e.g., index funds, Roth, brokerage). Step 5: Refocus on your core business—it's the biggest driver of your income, wealth, and eventual valuation. Five Wealth-Building Steps Reinvest first: Stop putting money into outside investments until your business is stable and growing. Scale income: Push until your take-home dwarfs your expenses, creating a true gap to invest. Avoid shiny tax tricks: Don't get lured into complex, illiquid strategies just to save on taxes. Automate simple wealth: Stick to straightforward, low-risk investments you don't need to micromanage. Refocus on the clinic: Your business is the asset that drives both income and long-term wealth potential. Why This Matters Cash flow: Clinics aren't tech startups with 10x exits, but they provide steady, strong cash flow. De-risking: Building wealth outside your business reduces stress and makes better decisions possible inside your business. Exit optionality: Even if you never sell, you've built income streams and assets that fund your life. Generational wealth: A smart clinic + simple investments can set up long-term family stability. Pro Tips You Can Use Today Audit reinvestment: Look at what you're spending outside your clinic and redirect into marketing, mentorship, or systems. Watch lifestyle creep: Don't inflate spending just because your clinic income grows. Vet opportunities: Only pursue investments you understand and can keep simple. Think barbell: Your clinic is the high-risk/high-reward side; balance it with simple, low-risk assets. Notable Quotes “The best financial decision I ever made was to stop investing outside of my clinic and pour it all back into growing my business.” “Don't let tax loopholes drive your investing. Solid investment first, tax benefit second.” “Your clinic is your core asset. Improve that, and everything else follows.” Action Items Redirect outside investments into your clinic until it's producing consistent profitability. Set a percentage of excess income for simple, automated investments once you have a surplus. Stop chasing tax shelters—pick straightforward, safe investments instead. Schedule time to review your clinic's systems, team, and profitability this quarter. Programs Mentioned Clinical Rainmaker: Coaching + plan to get you full-time in your clinic. Mastermind: Scale beyond yourself into space, team, and systems. PT Biz Part-Time to Full-Time 5-Day Challenge (Free): Get crystal clear on expenses, visit targets, pricing, 3 go-full-time paths, and a one-page plan. Resources & Links PT Biz Website Free 5-Day PT Biz Challenge About Danny: Over 15 years in the profession—staff PT, active-duty military PT, cash-practice founder and exit—now helping 1,000+ clinicians start, grow, and scale cash-based practices with PT Biz.

Today, I'm sitting down with Alex Tarnava and Dr. Tyler LeBaron, two of the brightest minds pioneering the use of molecular hydrogen in health optimization. Alex, the innovative creator behind the open cup hydrogen tablet technology, and Dr. LeBaron, founder of the Molecular Hydrogen Institute, join me to shed light on why this tiniest molecule could be the secret weapon in your longevity toolkit. We dive into their personal stories—Alex's relentless search for relief from autoimmune symptoms, and Dr. LeBaron's early curiosity that led him to decades of hydrogen research and advocacy.   To learn more visit  inhaleh2.com/NAT. There is a special discount between 20% - 24% percent off, depending on your pre-order.   Episode Timestamps: What is molecular hydrogen? ... 00:00:31 Guest backgrounds and early hydrogen research ... 00:04:37 Hydrogen's biological role and health benefits ... 00:09:24 Alex's personal health journey and invention ... 00:16:24 Clinical trials and real-world benefits ... 00:26:01 Hydrogen as a selective antioxidant ... 00:34:20 Inflammation, mitochondria, and aging ... 00:45:47 Delivery methods: water, inhalation, bathing ... 00:58:16 Dosing tips and protocols ... 01:14:21 Inhalation machines: safety and efficacy ... 01:17:47 Safety, final advice, and resources ... 01:26:26   Our Amazing Sponsors: StemRegen - A plant-based supplement protocol designed to enhance stem cell function. support your recovery, flexibility, and long-term vitality. Visit stemregen.co/NAT15 and use code: NAT15 for 15% off your order.   Puori - It's minimally processed, made from pasture-raised cows' milk, and it's tested for over 200 contaminants every single batch. Go to Puori.com/NAT and use code NAT for 20% off— it also applies to subscriptions so you'll get nearly a third off the price. OraltidePro- A unique mouthwash that: Promotes growth of shrinking gums, Speeds healing of mouth & tongue, Prevents oral infections (such as gingivitis), Helps with enamel remineralization, Reduces bacteria growth and etching and Fills slots in damaged enamel. check out OraltidePro at profound-health.com and use code NAT15 for 15% off your first order.   Nat's Links:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

If you're a practice owner who's always wondered, “how do I build a business so that I can create time freedom in my life”? Then this is an episode you're going to really love. In this episode of The Savvy Dentist Podcast, Dr. Jesse Green is speaking to Dr. Michael Filosi from Fullarton Park Dental in Adelaide. Michael has been on quite the journey over the last eight years. He bought a two chair practice, scaled that up to be an eight chair practice, and will soon be upgrading it to a 10 chair practice. In so doing, he's reduced his clinical hours down to zero which has given him immense freedom. Michael discusses his journey and explains some of the lessons he's learned along the way. Lessons that are going to be applicable to you if that's the journey you want to go on.In this episode:[3:58] - The original purchase back 9 years ago looked completely different to the efficient practice it is today.[8:27] - A wholesale practice purchase, verse, a partnership purchase.[11:34] - Having a very clear vision has helped Michael create and grow the business. He shares his tips on how to create that vision, and then how to work ‘hard' towards achieving the outcome.[22:16] - Michael describes in detail the process and learnings from starting with 2 chairs nine years ago … to 8 chairs today.[31:04] - Increasing the patient flow meant installing better more efficient communication systems. Michael explains how he did it and how his team embraced the growth of the practice.[44:30] - Moving to (almost) zero clinical hours afforded Michael freedom to do the things he loves the most.Join the free Savvy Dentist Facebook GroupFollow Dr Jesse Green on LinkedInVisit Savvy Dentist websiteMentioned in this episode:Transformational Training for Dental Practice TeamsIf you want to grow your practice, you need a high-performing team - but training takes time, effort, and resources you often don't have. That's why we created the Savvy Dentist Team Training Bundle - a 12-month program packed with five powerful courses, including our Practice Manager Masterclass, Front Desk All Stars, Hygiene & Therapy Heroes, Treatment Coordinator Training, and the Million Dollar Dentist course. Each course is delivered live via Zoom, and you'll also get access to past recordings, so you can onboard new team members anytime without starting from scratch. Want to scale your practice and build a winning team? Click on the link and join the waitlist. Team Training Bundle Sept 25

Today, Dr. Jeremie Piña discusses clinical hours for Medical School.    Like the podcast? Schedule a Free Initial Consultation with our team: https://bemo.ac/podbr-BeMoFreeConsult   Don't forget to subscribe to our channel and follow us on Facebook, Instagram, and Twitter for more great tips and other useful information!   YouTube: https://www.youtube.com/c/BeMoAcademicConsultingInc Facebook: https://www.facebook.com/bemoacademicconsulting Instagram: https://www.instagram.com/bemo_academic_consulting/ Twitter: https://twitter.com/BeMo_AC TikTok: https://www.tiktok.com/@bemoacademicconsulting

“It's 5pm and your Consultant (attending) has headed off home. A patient arrives in the resuscitation room blood spurting from a stab wound in the armpit. Join Roisin – a junior Major Trauma fellow, Prash – a surgical trainee, Max – a senior trauma surgery fellow, and Chris – a Consultant trauma surgeon, as we talk through decision making from point of injury to aftercare in this challenging trauma surgical case”. • Hosts: Bulleted list of host names, including title, institution, & social media handles if indicated 1.     Mr Prashanth Ramaraj. General Surgery trainee, Edinburgh rotation. @LonTraumaSchool 2.     Dr Roisin Kelly. Major Trauma Junior Clinical Fellow, Royal London Hospital.  3.     Mr Max Marsden. Resuscitative Major Trauma Fellow, Royal London Hospital. @maxmarsden83 4.     Mr Christopher Aylwin. Consultant Trauma & Vascular Surgeon and Co-Programme Director MSc Trauma Sciences at Queen Mary University of London. @cjaylwin • Learning objectives: Bulleted list of learning objectives. A)    To become familiar with prehospital methods of haemorrhage control in penetrating junctional injuries. B)     To recognise the benefits of prehospital blood product resuscitation in some trauma patients. C)     To follow the nuanced decision making in decision for CT scan in a patient with a penetrating junctional injury. D)    To describe the possible approaches to the axillary artery in the context of resuscitative trauma surgery. E)     To become familiar with decision making around intraoperative systemic anticoagulation in the trauma patient. F)     To become familiar with decision making on type of repair and graft material in vascular trauma. G)    To recognise the team approach in holistic trauma care through the continuum of trauma care. • References: Bulleted list of references with PubMed links. 1.    Perkins Z. et al., 2012. Epidemiology and Outcome of Vascular Trauma at a British Major Trauma Centre. EJVES. https://www.ejves.com/article/S1078-5884(12)00337-1/fulltext 2.    Ramaraj P., et al. 2025. The anatomical distribution of penetrating junctional injuries and their resource implications: A retrospective cohort study. Injury. https://www.injuryjournal.com/article/S0020-1383(24)00771-X/ 3.    Smith, S., et al. 2019. The effectiveness of junctional tourniquets: A systematic review and meta-analysis. J Trauma Acute Care Surg. https://journals.lww.com/jtrauma/abstract/2019/03000/the_effectiveness_of_junctional_tourniquets__a.20.aspx 4.    Rijnhout TWH, et al. 2019. Is prehospital blood transfusion effective and safe in haemorrhagic trauma patients? A systematic review and meta-analysis. Injury. https://www.injuryjournal.com/article/S0020-1383(19)30133-0/ 5.    Davenport R, et al. 2023. Prehospital blood transfusion: Can we agree on a standardised approach? Injury. https://www.injuryjournal.com/article/S0020-1383(22)00915-9. 6.    Borgman MA., et al. 2007. The Ratio of Blood Products Transfused Affects Mortality in Patients Receiving Massive Transfusions at a Combat Support Hospital. J Trauma Acute Care Surg. https://journals.lww.com/jtrauma/fulltext/2007/10000/the_ratio_of_blood_products_transfused_affects.13.aspx 7.    Holcomb JB., et al. 2013. The Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) Study. Comparative Effectiveness of a Time-Varying Treatment With Competing Risks. JAMA Surgery. https://jamanetwork.com/journals/jamasurgery/fullarticle/1379768 8.    Holcomb JB, et al. 2015. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma. The PROPPR Randomized Clinical Trial. JAMA. https://jamanetwork.com/journals/jama/fullarticle/2107789 9.    Davenport R., et al. 2023. Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury. The CRYOSTAT-2 Randomized Clinical Trial. JAMA. https://jamanetwork.com/journals/jama/fullarticle/2810756 10.   Baksaas-Aasen K., et al. 2020. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. ICM. https://link.springer.com/article/10.1007/s00134-020-06266-1 11. Wahlgren CM., et al. 2025. European Society for Vascular Surgery (ESVS) 2025 Clinical Practice Guidelines on the Management of Vascular Trauma. EJVES. https://esvs.org/wp-content/uploads/2025/01/2025-Vascular-Trauma-Guidelines.pdf 12. Khan S., et al. 2020. A meta-analysis on anticoagulation after vascular trauma. Eur J Traum Emerg Surg. https://link.springer.com/article/10.1007/s00068-020-01321-4 13. Stonko DP., et al. 2022. Postoperative antiplatelet and/or anticoagulation use does not impact complication or reintervention rates after vein repair of arterial injury: A PROOVIT study. Vascular. https://journals.sagepub.com/doi/10.1177/17085381221082371?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Contributor: Alec Coston, MD Case Report Summary: A 17-year-old female involved in a motor vehicle collision presented to a rural emergency facility via personally operated vehicle. During workup and initial CT scan, the patient began rapidly decompensating with CT revealing a 1.5cm epidural hematoma with 7mm of midline shift. The patient went from being able to walk and talk to being obtunded with a blown left pupil and unresponsive. Following intubation, the patient was being prepared for transport but potential delays required immediate emergency evacuation of the hematoma via a Burr Hole. A traditional Burr Drill was not immediately available at the facility, so an improvised Burr Drill using an Intraosseous (IO) drill was used. 35mL of blood was removed from the hematoma and the patient immediately improved from a GCS of 3 to GCS of 8. The patient was transferred to a higher level of care facility, extubated the following day, and made a full neurological recovery.  Educational Pearls: What is an epidural hematoma? An epidural hematoma is a collection of blood between the dura mater (outermost layer of the meninges) and the skull, whereas a subdural hematoma is a collection of blood between the dura mater and arachnoid mater. Both can be life threatening depending on location and size. Epidural hematomas tend to be arterial, and are typically secondary to trauma and can rapidly expand, but with timely recognition and evacuation of the bleed, favorable outcomes are often possible. What are typical intracranial pressures and at what levels do they become pathologic? Typical intracranial pressure (ICP) varies by age, but past infancy and early childhood, adolescents and adults have a value typically between 8-15mmHg. Values exceeding 20mmHg become pathologic and rise exponentially with increased volume. Initial symptoms may include headache, nausea, and vomiting, but with increased pressures may progress to more life threatening symptoms such as loss of consciousness, cranial nerve palsies, pupillary constriction or dilation (sign of herniation), and respiratory irregularities. What is the takeaway in timing of epidural hematomas? Older studies show that evacuation of a hematoma with lateralizing features before the two hour mark of coma symptom onset is correlated with decreased mortality (ranging from 15-17%), but beyond 2 hours the mortality increases to well over 50%. Though mortality statistics have grown more variable, early targeted evacuation of epidural hematomas still remains critical for improved patient outcomes. In austere conditions with limited resources, improvisation with interosseous drills and needles can improve patient outcomes and achieve the target therapy for epidural hematomas. References Haselsberger K, Pucher R, Auer LM. Prognosis after acute subdural or epidural haemorrhage. Acta Neurochir (Wien). 1988;90(3-4):111-116. doi:10.1007/BF01560563 Hawryluk GWJ, Nielson JL, Huie JR, et al. Analysis of Normal High-Frequency Intracranial Pressure Values and Treatment Threshold in Neurocritical Care Patients: Insights into Normal Values and a Potential Treatment Threshold. JAMA Neurol. 2020;77(9):1150-1158. doi:10.1001/jamaneurol.2020.1310 Pisică D, Volovici V, Yue JK, et al. Clinical and Imaging Characteristics, Care Pathways, and Outcomes of Traumatic Epidural Hematomas: A Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury Study. Neurosurgery. 2024;95(5):986-999. doi:10.1227/neu.0000000000002982 Summarized by Dan Orbidan, OMS2 | Edited by Dan Orbidan and Jorge Chalit, OMS4 Donate: https://emergencymedicalminute.org/donate/

In this conversation, Hallie Bulkin and Robyn Merkel Walsh discuss the resurgence of evidence-based practice (EBP) in myofunctional therapy, addressing the challenges faced in research acceptance and the misconceptions surrounding pseudoscience. They emphasize the importance of clinical insight, the role of therapy tools, and the need to address compensations in therapy. The discussion highlights the art and science of myofunctional therapy and concludes with a call to action for clinicians to focus on functional outcomes for their patients.In this episode, you'll learn:✔️There is a resurgence in evidence-based practice discussions in myofunctional therapy.✔️Misunderstandings about evidence-based practice can lead to misinformation.✔️Research acceptance in the field is often slow and complicated.✔️Pseudoscience is frequently misapplied to myofunctional therapy.✔️Clinical experience and patient outcomes are crucial components of evidence-based practice.✔️Tools in therapy can enhance learning and understanding for patients.✔️Compensations in therapy can lead to long-term issues if not addressed.✔️The conversation around myofunctional therapy is evolving, influenced by social media.✔️Understanding the nuances of therapy practices is essential for effective treatment.✔️The ultimate goal is to restore function for patients, not just treat symptoms.RELATED EPISODES YOU MIGHT LOVERELATED EPISODES YOU MIGHT LOVEEp 327: Understanding Holistic Dentistry & Myofunctional TherapyEp 334: Bye-Bye Thumb! Myo & Airway Strategies to Break the Habit - for GoodOTHER WAYS TO CONNECT & LEARNConnect with Robyn on her website: https://www.robynmerkelwalsh.com/

This episode started with a simple question I asked on social media: “What's a weird habit of yours that you wonder if it's tied to your ADHD/AuDHD?” Hundreds of responses came in. This is part 3 of this three part series. In this episode the themes explored are systems and rituals around time tricks, sorting, and hyperfocus. SHOW NOTES You Are A Lot Podcast On Patreon 7 Day Free Trial 30 FREE DAYS to BRAIN FM Wire Your Brain For Focus! Jen's Every 10 Day Newsletter: “This Is A Lot” Send an email to the podcast at alotadhdpod at gmail dot com 15% Off HUGIMALS weighted stuffed animals with code JENKIRKMAN You Are A Lot Podcast Website SOURCES USED: Visual Thinking by Temple Grandin 20% off Unmasking Autism by Devon Price 20% off Smart But Stuck by Dr. Thomas Brown 20% off Autism in Polyvagal Terms 20% off this book The ADHD Productivity Manual by Ari Tuckman 20% off this book Laziness Does Not Exist By Devon Price 20% off this book TLC Foundation For BFRB's Dr. Kieran Rose, autistic educator & advocate Stephen Porges, Polyvagal Theory  Dr. Aimee Daramus, Clinical psychologist/specialist in neurodivergent sensory issues   

Today my guest is Roseann Vitale, Product Manager with Mopec. What we discuss with Roseann: Roseann's path to the pathologists' assistant profession and how her background in fine arts influenced her career in pathology Helping to build a simulated pathology lab at Rosalind Franklin University Her innovative approaches to hands-on learning and standardization in PA education Her clinical experience in pediatric pathology and how it informed her teaching and professional perspective Transitioning from academia and clinical practice into an industry role at Mopec The role of Product Manager at Mopec and what it means to be the “voice of the customer” Challenges of variability and standardization at the grossing bench The Mopec–Lumea partnership and how integrating digital imaging at the grossing bench transforms workflows The creation and goals of the Mopec Clinical Advisory Board Roseann's involvement in professional organizations and how that influences her industry work Her vision for the future of pathology: smarter, safer, and more standardized workflows in grossing and anatomic pathology   Links for this episode: InVision from Cision Vision The Path to PathA Pathologists' Assistant Shadowing Network Health Podcast Network  LabVine Learning Dress A Med scrubs Digital Pathology Club   Mopec  Rosalind Franklin University Pathologists' Assistant Program Lumea Panel of National Pathology Leaders American Association of Pathologists' Assistants   People of Pathology Podcast: Twitter Instagram  

From ancient Sumerian epics to modern-day sightings in England's Cannock Chase, the werewolf has terrorized humanity for over 2,000 years — and the real history includes medieval trials that tortured and executed thousands of accused shapeshifters, medical conditions that spawned the legends, and 35 documented sightings in a single forest that continue to this day. Journey through the dark truth behind lycanthropy, from the She-Wolves of Jülich who allegedly killed 94 people to the shocking werewolf trials that made witch hunts look merciful, and discover why every culture on Earth has its own terrifying version of the wolf-human hybrid.Join the DARKNESS SYNDICATE for the ad-free version: https://weirddarkness.com/syndicateTake the WEIRD DARKNESS LISTENER SURVEY and help mold the future of the podcast: https://weirddarkness.com/surveyIN THIS EPISODE: The idea of the werewolf has been with us for a long time – the first mention of a werewolf that we know of is over two thousand years ago. We'll look at the origins of the werewolf, look at whether they are actually real, and if so, how one goes about becoming one, and some of the cures believed to release the man from the beast. Of course, it's not always the Wolf-Man… sometimes it's the Wolf-Woman. We'll look at the most fearsome lady werewolves throughout history! I'll tell you about the trials and punishments of those convicted of being werewolves – many probably wish they'd have confessed to being witches instead! Plus, what if I was to tell you that werewolves truly ARE real – and that a small village has been terrorized by them for decades – right up to modern day? There is convincing evidence to back up my claim! All of this and more werewolfism can be found in this episode!CHAPTERS & TIME STAMPS (All Times Approximate)…00:00:00.000 = Lead-In00:02:57.556 = Show Intro00:04:50.336 = Ancient Origins of Werewolves00:26:04.006 = Who's Afraid of Virginia Werewolf?00:35:55.899 = The Werewolf Trials00:48:53.940 = The Lycanthrope Metaphor00:54:10.432 = Lycans of Cannock Chase01:02:35.974 = Little-Known Lycan Lore01:05:35.605 = Show CloseSOURCES AND RESOURCES FROM THE EPISODE…BOOK: “Giants, Monsters and Dragons” by Carol Rose: https://amzn.to/36k0VW0BOOK: “The Werewolf Delusion” by Ian Woodward: https://amzn.to/2Sa74LVBOOK: “The Book of Werewolves” by Reverend Sabine Baring-Gould: https://amzn.to/3jgTLp5EPISODE: “The Werewolf Panic of the 1970's”: https://weirddarkness.tiny.us/48s5bbkk EPISODE: “Werewolves of Central England”: https://weirddarkness.tiny.us/2vpt52rn EPISODE: “Werewolf In The Bronx”: https://weirddarkness.tiny.us/y3auryjk EPISODE: “A Summer of Werewolves”: https://weirddarkness.tiny.us/2p875ynn EPISODE: “Planet Werewolf”: https://weirddarkness.tiny.us/yb6ck67a EPISODE: “The Beast Of The Land Between The Lakes”: https://weirddarkness.tiny.us/5n8jcczz EPISODE: “The Beast of Barmston Drain”: https://weirddarkness.tiny.us/mrs9j8xu EPISODE: “The Ohio Dogman”: https://weirddarkness.tiny.us/2p8rc5su EPISODE: “The Skinwalker Ranch, Home To Real Werewolves”: https://weirddarkness.tiny.us/2p975j56 EPISODE: “Hairy Humanoids of Texas”: https://weirddarkness.tiny.us/yckkfhun EPISODE: “Skinwalkers and Shapeshifters”: https://weirddarkness.tiny.us/mr2w57xr VIDEO: “A Brief History of Horror – Werewolves”: https://www.youtube.com/watch?v=tBLcGH1MpRgVIDEO: “Legends of the Werewolves”: https://www.youtube.com/watch?v=HCHZjU7Hi0w“The Origins and Lore of Werewolves” from History Daily: https://tinyurl.com/y4l7ytmk, Tanika Koosmen for The Conversation: https://tinyurl.com/y5jy9uog, Benjamin Radford for Live Science: https://tinyurl.com/yclcqmqp, and Ella Talkin for Ranker: https://tinyurl.com/yy55wq9q“The Werewolf Trials” by Inigo Gonzalez for Ranker: https://tinyurl.com/y2qmp4n2“The Lycans of Cannock Chase” by Hugh Landman for Ranker: https://tinyurl.com/s6h83am“Who's Afraid of Virginia Werewolf?” by April A Taylor for Ranker: https://tinyurl.com/y3qz82on“How Werewolves Work” by Tracy V.V. Wilson for How Stuff Works: https://tinyurl.com/y3oe9bte“Little-Known Lycan Lore” by Jonathan Gordon for History Answers: https://tinyurl.com/y3jb5scq=====(Over time links may become invalid, disappear, or have different content. I always make sure to give authors credit for the material I use whenever possible. If I somehow overlooked doing so for a story, or if a credit is incorrect, please let me know and I will rectify it in these show notes immediately. Some links included above may benefit me financially through qualifying purchases.)= = = = ="I have come into the world as a light, so that no one who believes in me should stay in darkness." — John 12:46= = = = =WeirdDarkness® is a registered trademark. Copyright ©2025, Weird Darkness.=====Originally aired: September 30, 2020EPISODE PAGE at WeirdDarkness.com (includes list of sources): https://weirddarkness.com/werewolvesABOUT WEIRD DARKNESS: Weird Darkness is a true crime and paranormal podcast narrated by professional award-winning voice actor, Darren Marlar. Seven days per week, Weird Darkness focuses on all thing strange and macabre such as haunted locations, unsolved mysteries, true ghost stories, supernatural manifestations, urban legends, unsolved or cold case murders, conspiracy theories, and more. On Thursdays, this scary stories podcast features horror fiction along with the occasional creepypasta. Weird Darkness has been named one of the “Best 20 Storytellers in Podcasting” by Podcast Business Journal. Listeners have described the show as a cross between “Coast to Coast” with Art Bell, “The Twilight Zone” with Rod Serling, “Unsolved Mysteries” with Robert Stack, and “In Search Of” with Leonard Nimoy.DISCLAIMER: Ads heard during the podcast that are not in my voice are placed by third party agencies outside of my control and should not imply an endorsement by Weird Darkness or myself. *** Stories and content in Weird Darkness can be disturbing for some listeners and intended for mature audiences only. Parental discretion is strongly advised.#Werewolves #TrueCrime #Paranormal #MedievalHistory #Cryptozoology

In this episode of The Lindsey Elmore Show, we dive into an intimate corner of peptide therapy—sexual health and desire. Lindsey explores two cutting-edge peptides, PT-141 (bremelanotide) and Kisspeptin, both of which show promise in enhancing sexual pleasure, intimacy, and overall satisfaction for women and men alike.She unpacks how PT-141, originally developed as a tanning agent, is now FDA-approved for hypoactive sexual desire disorder in premenopausal women, and how Kisspeptin is showing powerful results in clinical trials by boosting arousal while quieting guilt and self-consciousness in the brain.While these peptides may open new doors for intimacy and connection, Lindsey also reminds us that chemistry is only part of the equation—emotional intimacy and relational work remain essential.Key TakeawaysWhat Peptide Therapy Is (00:01–00:05) Small chains of amino acids can enhance multiple body systems, including sexual health.PT-141 (Bremelanotide) (00:16–02:29) Originally a tanning agent, now FDA-approved for treating hypoactive sexual desire disorder in premenopausal women. Increases both desire and pleasure, though some users experience nausea or flushing.Safety & Sourcing (02:43–03:12) Avoid unregulated sprays found online; only use compounding pharmacies for safety and consistency.Kisspeptin Research (03:34–05:35) A neuropeptide was first discovered in cancer research. Clinical studies show it activates arousal-related brain regions while quieting guilt and self-consciousness. Found effective in both women and men, improving desire, arousal, and satisfaction.Emotional & Relational Context (05:59–06:59) Peptides may enhance sexual function, but emotional intimacy, cultural context, and relational dynamics are still central to true sexual well-being.Where the Field is Headed (07:02–07:09) Future episodes will explore peptide research in pain management and hormone regulation.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-lindsey-elmore-show--5952903/support.

Golf correspondent Iain Carter & commentator Kat Downes join John Murray & Ali Bruce-Ball from the Ryder Cup. They talk about John's travel trevails and his unexpected personal shopping experience. Why will commentating at this Ryder Cup be different? Who will we raise a glass to after Clash of the Commentators? And more suggestions for the Great Glossary of Football Commentary. Get your suggestions in with WhatsApp voicenotes to 08000 289 369 & emails to TCV@bbc.co.uk01:45 Does the Ryder Cup beat all other golf events? 04:10 John's travel travails mean 24 hours awake 05:45 John's personal shopping experience 07:50 Commentating on the tee shots 14:00 Could politics make for hostile atmosphere? 15:45 John's encounters with American supporters 20:35 Commentator Kat Downes joins the pod 23:45 Ali getting hit on the head by a tee shot 31:05 Fine facial fuzz & more pub names 34:30 5 Live football commentaries this weekend 38:45 Clash of the Commentators 45:10 Great Glossary of Football Commentary 48:30 Who's the most ‘one for the cameras' golferBBC Sounds / 5 Live commentaries: Sat 1500 Crystal Palace v Liverpool, Sat 1500 Chelsea v Brighton on Sports Extra, Sat 1730 Nottingham Forest v Sunderland on Sports Extra, Sun 1400 Aston Villa v Fulham, Sun 1630 Newcastle v Arsenal on Sports Extra.Glossary so far:DIVISION ONE Cryuff TurnDIVISION TWO Howler One for the cameras Root and branch review Row Z Taking one for the team That's great… (football) Thunderous strikeUNSORTED 2-0 is a dangerous score, After you Claude, All-Premier League affair, Aplomb, Bag/box of tricks, Brace, Brandished, Breaking the deadlock, Bundled over the line, Champions elect / champions apparent, Clinical finish, Commentator's curse, Coupon buster, Cultured/Educated left foot, Denied by the woodwork, Draught excluder, Elimination line, Fellow countryman, Foot race, Formerly of this parish, Fox in the box, Free hit, Goalkeepers' Union, Goalmouth scramble, Good touch for a big man, Honeymoon Period, In and around, In the shop window, Keeping ball under their spell, Keystone Cops defending, Languishing, Loitering with intent, Marching orders, Nestle in the bottom corner, Numbered derbies, Nutmeg, Opposite number, Park the bus, PK for penalty-kick, Postage stamp, Put it in the mixer, Put their laces through it, Rasping shot, Red wine not white wine, Relegation six-pointer, Rooted at the bottom, Route One, Roy of the Rovers stuff, Sending the goalkeeper the wrong way, Shooting boots, Sleeping giants, Slide rule pass, Small matter of, Spiders web, Stayed hit, Steepling, Stinging the palms, Stonewall penalty, Straight off the training ground, Stramash, Taking one for the team, Team that likes to play football, Throw their cap on it, Thruppenny bit head / 50p head, Towering header, Two good feet, Turning into a basketball match, Turning into a cricket score, Usher/Shepherd the ball out of play, Walking a disciplinary tightrope, Wand of a left foot, We've got a cup tie on our hands, Where the kookaburra sleeps, Where the owl sleeps, Winger in their pocket, Wrap foot around it, Your De Bruynes, your Gundogans etc.